| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FCA.09.33 |
| P698 | PubMed publication ID | 19715412 |
| P2093 | author name string | Pierre Fontana | |
| Henri Bounameaux | |||
| Alexandra Santana Sorensen | |||
| Jessica Mann | |||
| Kjell S Sakariassen | |||
| Peteris Alberts | |||
| P2860 | cites work | Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force | Q22305330 |
| Testosterone Increases Human Platelet Thromboxane A2 Receptor Density and Aggregation Responses | Q22306390 | ||
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder | Q24633040 | ||
| Nephrotic syndrome in adults | Q24650808 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| Aspirin resistance | Q28167475 | ||
| Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study | Q28171078 | ||
| Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy | Q28192250 | ||
| Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects | Q28193542 | ||
| Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway | Q28196567 | ||
| Approaches to prevention of cardiovascular complications and events in diabetes mellitus | Q28209964 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review | Q28217967 | ||
| Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection | Q28218540 | ||
| New antiplatelet strategies in atherothrombosis and their indications | Q28219458 | ||
| Cell signalling through thromboxane A2 receptors | Q28241544 | ||
| Vascular endothelial cells synthesize nitric oxide from L-arginine | Q28291036 | ||
| Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis | Q28316203 | ||
| Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes | Q28316520 | ||
| Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis | Q28362606 | ||
| Additions and Corrections to Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A(2) receptor | Q30051401 | ||
| Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. | Q34017497 | ||
| Prostanoid receptors: subtypes and signaling | Q34192781 | ||
| The isoprostanes in biology and medicine | Q34303635 | ||
| Aspirin as an antiplatelet drug | Q34338650 | ||
| Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement | Q34964056 | ||
| Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis | Q35593380 | ||
| Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor | Q35793184 | ||
| Isoprostanes and the kidney | Q36009409 | ||
| Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management | Q36180173 | ||
| From the design to the clinical application of thromboxane modulators | Q36419627 | ||
| Insights into oxidative stress: the isoprostanes | Q36754565 | ||
| Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. | Q36887785 | ||
| Prostaglandins in the kidney: developments since Y2K. | Q36924292 | ||
| A role for the thromboxane receptor in L-NAME hypertension | Q36956758 | ||
| Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. | Q37385355 | ||
| Antithrombotic agents in the prevention of ischemic stroke | Q37480441 | ||
| Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study | Q37480454 | ||
| Update on oral antiplatelet therapy: principles, problems and promises | Q37486605 | ||
| Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. | Q40978901 | ||
| Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. | Q42249127 | ||
| Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis | Q42281442 | ||
| Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease | Q43841703 | ||
| Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats. | Q44321794 | ||
| The Thromboxane Receptor Antagonist PBT-3, a Hepoxilin Stable Analog, Selectively Antagonizes the TPα Isoform in Transfected COS-7 Cells | Q44618366 | ||
| Role for thromboxane receptors in angiotensin-II-induced hypertension. | Q44725166 | ||
| Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats | Q44944758 | ||
| Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration | Q44970389 | ||
| Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy | Q45012594 | ||
| Thromboxane receptor blockade reduces renal injury in murine lupus nephritis | Q45055157 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study | Q45181167 | ||
| Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study | Q45285281 | ||
| Increased platelet thromboxane synthesis in renal glomerular diseases | Q45791338 | ||
| The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 | ||
| Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests | Q46265322 | ||
| Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. | Q46418076 | ||
| The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease | Q46505199 | ||
| The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. | Q46566202 | ||
| The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension | Q46985304 | ||
| Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients | Q47734969 | ||
| Role of ADP and thromboxanes in human thrombus formation in ex vivo models. | Q51174787 | ||
| Carotid artery disease in NIDDM diabetes. | Q51645371 | ||
| The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. | Q54019410 | ||
| Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients | Q58823394 | ||
| Effects of Picotamide, an Antithromboxane Agent, on Carotid Atherosclerotic Evolution | Q58823405 | ||
| Synthesis and structure of the platelet aggregation factor thromboxane A2 | Q59062122 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 479-493 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Future Cardiology | Q15765184 |
| P1476 | title | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases | |
| P478 | volume | 5 |
| Q38172461 | Antiplatelet therapy: targeting the TxA2 pathway. |
| Q33608615 | Cyclic nucleotide-gated channels contribute to thromboxane A2-induced contraction of rat small mesenteric arteries |
| Q28481694 | Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 |
| Q34622554 | Drug strategies targeting CYP51 in neglected tropical diseases |
| Q34389439 | Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. |
| Q89219277 | Investigation of a Thromboxane A2 Receptor-Based Vaccine for Managing Thrombogenesis |
| Q53798598 | Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. |
| Q55399934 | Prostaglandins in the pathogenesis of kidney diseases. |
| Q46637396 | Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation |
Search more.